Dipeptidyl peptidase 4 inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dipeptidyl Peptidase 4 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Dipeptidyl Peptidase 4 Inhibitors: Overview
Dipeptidyl-peptidase-4 (DPP4, also known as CD26) is a membrane glycoprotein that is well known for its role in the catalytic degradation of incretins. DPP4 inhibitors (DPP4i), as a class of antidiabetic medications, have been accepted worldwide, owing to their ease of administration, modest effects on HbA1c, and lack of serious side effects. DPP4 inhibition in experimental models has uniformly demonstrated cardioprotective effects.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and may be used in the treatment of type 2 diabetes. DPP-4 inhibitors slow the inactivation and degradation of GLP-1, a hormone involved in glucose removal from the gut. DPP-4 inhibitors improve blood glucose control and reduce both fasting and postprandial (after food) blood glucose levels, without causing weight gain. They do not usually cause hypoglycemia (low blood sugar levels) unless they are combined with other therapies that cause hypoglycemia.
Report Highlights
This segment of the Dipeptidyl Peptidase 4 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dipeptidyl Peptidase 4 Inhibitors Emerging Drugs
It is currently in Phase III stage of development and is being developed by Haisco Pharmaceutical Group.
Further product details are provided in the report……..
Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Dipeptidyl Peptidase 4 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Dipeptidyl Peptidase 4 Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dipeptidyl Peptidase 4 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dipeptidyl Peptidase 4 Inhibitors drugs.
Dipeptidyl Peptidase 4 Inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Dipeptidyl Peptidase 4 Inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Dipeptidyl Peptidase 4 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Dipeptidyl Peptidase 4 Inhibitors: Overview
Dipeptidyl-peptidase-4 (DPP4, also known as CD26) is a membrane glycoprotein that is well known for its role in the catalytic degradation of incretins. DPP4 inhibitors (DPP4i), as a class of antidiabetic medications, have been accepted worldwide, owing to their ease of administration, modest effects on HbA1c, and lack of serious side effects. DPP4 inhibition in experimental models has uniformly demonstrated cardioprotective effects.
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and may be used in the treatment of type 2 diabetes. DPP-4 inhibitors slow the inactivation and degradation of GLP-1, a hormone involved in glucose removal from the gut. DPP-4 inhibitors improve blood glucose control and reduce both fasting and postprandial (after food) blood glucose levels, without causing weight gain. They do not usually cause hypoglycemia (low blood sugar levels) unless they are combined with other therapies that cause hypoglycemia.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Dipeptidyl Peptidase 4 Inhibitors R&D. The therapies under development are focused on novel approaches for Dipeptidyl Peptidase 4 Inhibitors.
This segment of the Dipeptidyl Peptidase 4 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Dipeptidyl Peptidase 4 Inhibitors Emerging Drugs
- HSK7653: Haisco Pharmaceutical Group
It is currently in Phase III stage of development and is being developed by Haisco Pharmaceutical Group.
- DA-1229: Dong-A ST
Further product details are provided in the report……..
Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Dipeptidyl Peptidase 4 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Dipeptidyl Peptidase 4 Inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Dipeptidyl Peptidase 4 Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Dipeptidyl Peptidase 4 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dipeptidyl Peptidase 4 Inhibitors drugs.
Dipeptidyl Peptidase 4 Inhibitors Report Insights
- Dipeptidyl Peptidase 4 Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Dipeptidyl Peptidase 4 Inhibitors drugs?
- How many Dipeptidyl Peptidase 4 Inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Dipeptidyl Peptidase 4 Inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dipeptidyl Peptidase 4 Inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Dipeptidyl Peptidase 4 Inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Boehringer Ingelheim
- Haisco Pharmaceutical Group
- BioXcel Therapeutics
- Recardio
- Dong-A ST
- CSPC ZhongQi Pharmaceutical Technology
- Chia Tai Tianqing Pharmaceutical Group
- Linagliptin
- HSK7653
- BXCL 701
- Dutogliptin
- DA-1229
- DBPR108
- TQ-F3083
Introduction
Executive Summary
Dipeptidyl Peptidase 4 Inhibitors : Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dipeptidyl Peptidase 4 Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Dipeptidyl Peptidase 4 Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dipeptidyl Peptidase 4 Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
HSK7653: Haisco Pharmaceutical Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Dutogliptin: Recardio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Dipeptidyl Peptidase 4 Inhibitors Key Companies
Dipeptidyl Peptidase 4 Inhibitors Key Products
Dipeptidyl Peptidase 4 Inhibitors - Unmet Needs
Dipeptidyl Peptidase 4 Inhibitors - Market Drivers and Barriers
Dipeptidyl Peptidase 4 Inhibitors - Future Perspectives and Conclusion
Dipeptidyl Peptidase 4 Inhibitors Analyst Views
Dipeptidyl Peptidase 4 Inhibitors Key Companies
Appendix
Executive Summary
Dipeptidyl Peptidase 4 Inhibitors : Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dipeptidyl Peptidase 4 Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Dipeptidyl Peptidase 4 Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Dipeptidyl Peptidase 4 Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
HSK7653: Haisco Pharmaceutical Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Dutogliptin: Recardio
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Dipeptidyl Peptidase 4 Inhibitors Key Companies
Dipeptidyl Peptidase 4 Inhibitors Key Products
Dipeptidyl Peptidase 4 Inhibitors - Unmet Needs
Dipeptidyl Peptidase 4 Inhibitors - Market Drivers and Barriers
Dipeptidyl Peptidase 4 Inhibitors - Future Perspectives and Conclusion
Dipeptidyl Peptidase 4 Inhibitors Analyst Views
Dipeptidyl Peptidase 4 Inhibitors Key Companies
Appendix
